Cytokinetics plans supplemental NDA submission for aficamten in Q4 2026
Cytokinetics plans to submit a supplemental NDA to the U.S. FDA for aficamten in Q4 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.